Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Advances in Brief

NY-ESO-1 Expression and Immunogenicity Associated with Transitional Cell Carcinoma

Correlation with Tumor Grade

Takushi Kurashige, Yuji Noguchi, Takashi Saika, Toshiro Ono, Yasuhiro Nagata, Achim Jungbluth, Gerd Ritter, Yao-Tseng Chen, Elisabeth Stockert, Tomoyasu Tsushima, Hiromi Kumon, Lloyd J. Old and Eiichi Nakayama
Takushi Kurashige
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuji Noguchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Saika
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshiro Ono
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuhiro Nagata
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Achim Jungbluth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerd Ritter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yao-Tseng Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth Stockert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomoyasu Tsushima
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiromi Kumon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lloyd J. Old
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eiichi Nakayama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published June 2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    A, RT-PCR analysis for NY-ESO-1 mRNA expression. mRNA from G1 TCC (Lane 1), G2 TCC (Lanes 2–5), G3 TCC (Lanes 6–8), a human bladder cancer cell line, T24 (Lane 9), and testis (Lane 10) was analyzed for NY-ESO-1 mRNA by RT-PCR. B, H&E staining (left) and immunohistostaining for NY-ESO-1 using mAb ES121 (right) in serial sections of G1, G2, or G3 TCC.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    NY-ESO-1 antibody in patients with G3 TCC. Serially diluted sera from 5 patients with G3 TCC (•), serum from an NY-ESO-1-positive patient (○), and sera from 5 healthy volunteers (□) are shown. ELISA tests with recombinant NY-ESO-1 protein are also shown.

Tables

  • Figures
  • Table 1

    Correlation between NY-ESO-1 mRNA expression and pathological and clinical features in transitional cell carcinoma

    Pathological and clinical featuresNY-ESO-1 positive/tumors examined
    All tumors20/62 (32%)
    Tumor gradea
     G10/4 (0%)
     G26/26 (23%)
     G314/32 (44%)
    Tumor invasion
     Superficial10/36b (28%)
     Muscle invasion10/26 (38%)
    Regional lymph node metastasis
     Negative16/54 (30%)
     Positive4/8 (50%)
    Systemic metastasis
     Negative16/57 (28%)
     Positive4/5 (80%)
    • a The difference in frequency of NY-ESO-1 mRNA expression between high-grade (G3; 14 of 32) and low-grade (G1 and G2; 6 of 30) tumors was statistically significant (P < 0.05). Statistical analysis was performed by χ2 test.

    • b In this series of 36 superficial tumors, 3 were CIS, and 2 of the 3 CIS were NY-ESO-1 positive.

  • Table 2

    NY-ESO-1 antibody response in 124 patients with transitional cell carcinomaa

    Tumor gradeAntibody positive/sera tested
    G10/5 (0%)
    G20/47 (0%)
    G39/72b (12.5%)
    • a In this series of 124 patients with TCC, both frozen tumors and sera were available from 45 patients for NY-ESO-1 RT-PCR and antibody typing. Thirteen of 45 tumors were positive for NY-ESO-1 mRNA, and 2 of the 13 patients with NY-ESO-1-positive tumors had NY-ESO-1 antibody. No NY-ESO-1 antibody was found in the 32 patients with NY-ESO-1-negative tumors.

    • b The difference in NY-ESO-1 antibody frequency in patients with high-grade (G3; 9 of 72) and low-grade (G1 and G2; 0 of 52) tumors was statistically significant (P < 0.05). Statistical analyses were performed by χ2 test.

  • Table 3

    TNM classification of TCC in patients with NY-ESO-1 antibody

    PatientPrimary tumorMetastasis
    Regional lymph nodeSystemic
    TCC 11CIS−−
    TCC 18aT1 + CIS−−
    TCC 21T3b−−
    TCC 22aT4++
    TCC 25CIS−−
    TCC 38T2−−
    TCC 44bCIS−−
    TCC 84aT1 + CIS−−
    TCC 91T3b−−
    • a Tumor specimens with NY-ESO-1 expression confirmed by immunohistostaining. Frozen specimens from TCC18 for RT-PCR were not available.

    • b Patient TCC44 has been tumor free since September 1995 after transurethral resection of bladder tumor followed by BCG immunotherapy. Serum for NY-ESO-1 antibody test was obtained in October 1997. Sera from the 8 other patients were obtained at the time of surgical resection of their tumors.

PreviousNext
Back to top
Cancer Research: 61 (12)
June 2001
Volume 61, Issue 12
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
NY-ESO-1 Expression and Immunogenicity Associated with Transitional Cell Carcinoma
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
NY-ESO-1 Expression and Immunogenicity Associated with Transitional Cell Carcinoma
Takushi Kurashige, Yuji Noguchi, Takashi Saika, Toshiro Ono, Yasuhiro Nagata, Achim Jungbluth, Gerd Ritter, Yao-Tseng Chen, Elisabeth Stockert, Tomoyasu Tsushima, Hiromi Kumon, Lloyd J. Old and Eiichi Nakayama
Cancer Res June 15 2001 (61) (12) 4671-4674;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
NY-ESO-1 Expression and Immunogenicity Associated with Transitional Cell Carcinoma
Takushi Kurashige, Yuji Noguchi, Takashi Saika, Toshiro Ono, Yasuhiro Nagata, Achim Jungbluth, Gerd Ritter, Yao-Tseng Chen, Elisabeth Stockert, Tomoyasu Tsushima, Hiromi Kumon, Lloyd J. Old and Eiichi Nakayama
Cancer Res June 15 2001 (61) (12) 4671-4674;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • NIMA-Related Protein Kinase 1 Is Involved Early in the Ionizing Radiation-Induced DNA Damage Response
  • Conditional Expression of K-ras in an Epithelial Compartment that Includes the Stem Cells Is Sufficient to Promote Squamous Cell Carcinogenesis
  • 2-Arachidonoylglycerol
Show more Advances in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement